SequelSEC

Translational Development Acquisition Corp. TDAC

Blank Checks · CIK 0001926599 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$944.54K
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Translational Development Acquisition Corp. (TDAC) reported net income of $6.36M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Translational Development Acquisition Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Blank Checks.

Income

Translational Development Acquisition Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$944.54K-$196.36K-$485.55K
Net income$6.36M-$71.01K-$485.55K
Research & developmentUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailable$0Unavailable
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$944.54K$196.36KUnavailable
Selling & marketingUnavailableUnavailableUnavailable

Balance

Translational Development Acquisition Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$29.79K$438.17K$2.02K
Total assets$181.70M$175.00M$2.02K
Current assets$39.46K$650.23K$2.02K
Total liabilities$6.58M$6.25M$509.68K
Current liabilities$544.07K$210.30K$509.68K
Total equity incl. NCI-$6.54M-$5.60M-$507.66K
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payableUnavailable$16.19K$1.25K

Cash flow

Translational Development Acquisition Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$608.39K-$851.45K-$204
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailable-$174.22MUnavailable
Financing cash flow$200.00K$175.51MUnavailable
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Translational Development Acquisition Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.07x3.09x0.00x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TDAC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AACI AACO ADAC AEAQ AESP AEXA AFJK AIIA ALCYF ALDA ALDF ALFUU

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-12-31

Difference 181657311 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-12-31

Difference 174350346 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.